Affimed NV Price, Forecast, Insider, Ratings, Fundamentals & Signals

Heidelberg, germany, june 30, 2022 (globe newswire) -- affimed n.v. (nasdaq: afmd) (“affimed”, or the “company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the establishment of a scientific advisory board (sab) of renowned experts in their respective fields to provide scientific and clinical guidance on the development of affimed's innate cell engagers (ice®) programs.

Heidelberg, germany, june 10, 2022 (globe newswire) -- affimed n.v. (nasdaq: afmd) (“affimed” or the “company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the annual meeting of the european hematology association (eha) in vienna, austria. the data demonstrate the cytotoxic potential of the cd123/cd16a-targeting bispecific innate cell engager (ice®) afm28 which is in development as a novel treatment for patients with myeloid diseases, e. g. relapsed/refractory (r/r) acute myeloid leukemia (aml). afm28 binds to natural killer (nk) cells and cd123-positive tumor cells and demonstrated the induction of tumor cell killing in vitro and a good tolerability and strong anti-tumor activity in vivo.

Heidelberg, germany, june 01, 2022 (globe newswire) -- affimed n.v. (nasdaq: afmd) (“affimed” or the “company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the first quarter ended march 31, 2022 and provided an update on clinical and corporate progress.

Heidelberg, germany, may 26, 2022 (globe newswire) -- affimed n.v. (nasdaq: afmd), (“affimed”, or the “company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that three abstracts of clinical trial designs of its afm24 innate cell engager (ice®) have been published and will be presented at the american society of clinical oncology (asco) annual meeting, taking place on june 3-7, 2022 in chicago, il.

Heidelberg, germany, may 24, 2022 (globe newswire) -- affimed n.v. (nasdaq: afmd) (“affimed”, or the “company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2022 annual general meeting of shareholders (the “annual meeting”) will be held on june 22, 2022 at 09:00 a.m. cet at the radisson blu hotel, amsterdam city center, rusland 17, 1012 ck amsterdam, the netherlands.

Affimed has generated an impressive pipeline of innate cell engagers programs created using their three-pronged development strategy. These programs target high unmet needs and large market opportunities. Affimed recently finalized a $103.5M public offering, which will help fund the company's wholly-owned programs to hit key catalysts over the remainder of 2022 and into 2023.

Affimed N.V. (NASDAQ:AFMD ) Q1 2022 Results Conference Call June 1, 2022 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Wolfgang Fischer - Chief Operating Officer Angus Smith - Chief Financial Officer Conference Call Participants Daina Graybosch - SVB Securities Kripa Devarakonda - Truist Securities Maury Raycroft - Jefferies Li Watsek - Cantor Brad Canino - Stifel Do Kim with - Sandler Yale Jen - Laidlaw Nick Abbott - Wells Fargo Operator Good day and thank you for standing by.

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022.

HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. Eastern Daylight Time / 19:00 Central European Time.

Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2022 results and corporate update on Wednesday, June 1, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

HEIDELBERG, Germany, May 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an upcoming poster presentation demonstrating the cytotoxic potential of its CD123/CD16A-targeting innate cell engager (ICE®) AFM28 at the Annual Meeting of the European Hematology Association (EHA) to be held in Vienna, Austria on June 9 - 12, 2022.

Affimed N.V. (NASDAQ: AFMD) provided a data update from its ongoing study of lead innate cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells.

The biotech's experimental blood cancer treatment could be a major advancement.

Shares of Affimed AFMD, -6.14% were up 12.6% in premarket trading on Monday, the day after the company shared promising data about an experimental cancer therapy that uses cord blood cells. "The new data cut showed deepening of complete responses and early signs of durability that we believe are validating for the program and overall approach," SVB Leerink analyst Daina Graybosch told investors on Monday morning.